Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity

Aim. To evaluate whether the combination of the peripheral blood CD4+ adenosine triphosphate activity (ATP) assay (ImmuKnow assay: IMK assay) and cytochrome P450 3A5 (CYP3A5) genotype assay is useful for monitoring of immunological aspects in the patient followup of more than one year after living d...

Full description

Saved in:
Bibliographic Details
Main Authors: Shugo Mizuno, Yuichi Muraki, Kaname Nakatani, Akihiro Tanemura, Naohisa Kuriyama, Ichiro Ohsawa, Yoshinori Azumi, Masashi Kishiwada, Masanobu Usui, Hiroyuki Sakurai, Masami Tabata, Norihiko Yamamoto, Tomomi Yamada, Katsuya Shiraki, Yoshiyuki Takei, Tsutomu Nobori, Masahiro Okuda, Shuji Isaji
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2013/982163
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850159921542201344
author Shugo Mizuno
Yuichi Muraki
Kaname Nakatani
Akihiro Tanemura
Naohisa Kuriyama
Ichiro Ohsawa
Yoshinori Azumi
Masashi Kishiwada
Masanobu Usui
Hiroyuki Sakurai
Masami Tabata
Norihiko Yamamoto
Tomomi Yamada
Katsuya Shiraki
Yoshiyuki Takei
Tsutomu Nobori
Masahiro Okuda
Shuji Isaji
author_facet Shugo Mizuno
Yuichi Muraki
Kaname Nakatani
Akihiro Tanemura
Naohisa Kuriyama
Ichiro Ohsawa
Yoshinori Azumi
Masashi Kishiwada
Masanobu Usui
Hiroyuki Sakurai
Masami Tabata
Norihiko Yamamoto
Tomomi Yamada
Katsuya Shiraki
Yoshiyuki Takei
Tsutomu Nobori
Masahiro Okuda
Shuji Isaji
author_sort Shugo Mizuno
collection DOAJ
description Aim. To evaluate whether the combination of the peripheral blood CD4+ adenosine triphosphate activity (ATP) assay (ImmuKnow assay: IMK assay) and cytochrome P450 3A5 (CYP3A5) genotype assay is useful for monitoring of immunological aspects in the patient followup of more than one year after living donor liver transplantation (LDLT). Methods. Forty-nine patients, who underwent LDLT more than one year ago, were randomly screened by using IMK assay from January 2010 to December 2011, and the complete medical records of each patient were obtained. The CYP3A5 genotypes were examined in thirty-nine patients of them. Results. The mean ATP level of the IMK assay was significantly lower in the patients with infection including recurrence of hepatitis C (HCV) () than in those without infection (): 185 versus 350 ng/mL (), while it was significantly higher in the patients with rejection () than in those without rejection (): 663 versus 306 ng/mL (). The IMK assay showed favorable sensitivity/specificity for infection (0.909/0.842) as well as acute rejection (1.0/0.911). CYP3A5 genotypes in both recipient and donor did not affect incidence of infectious complications. Conclusions. In the late phase of LDLT patients, the IMK assay is very useful for monitoring immunological aspects including bacterial infection, recurrence of HCV, and rejection.
format Article
id doaj-art-b611ed07ef3d4001b404b4f6d8978841
institution OA Journals
issn 1740-2522
1740-2530
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Clinical and Developmental Immunology
spelling doaj-art-b611ed07ef3d4001b404b4f6d89788412025-08-20T02:23:19ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/982163982163Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate ActivityShugo Mizuno0Yuichi Muraki1Kaname Nakatani2Akihiro Tanemura3Naohisa Kuriyama4Ichiro Ohsawa5Yoshinori Azumi6Masashi Kishiwada7Masanobu Usui8Hiroyuki Sakurai9Masami Tabata10Norihiko Yamamoto11Tomomi Yamada12Katsuya Shiraki13Yoshiyuki Takei14Tsutomu Nobori15Masahiro Okuda16Shuji Isaji17Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Pharmacy, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Molecular and Laboratory Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Gastroenterology and Hepatology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanTranslational Medical Science, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Gastroenterology and Hepatology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Gastroenterology and Hepatology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Molecular and Laboratory Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Pharmacy, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanDepartment of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, JapanAim. To evaluate whether the combination of the peripheral blood CD4+ adenosine triphosphate activity (ATP) assay (ImmuKnow assay: IMK assay) and cytochrome P450 3A5 (CYP3A5) genotype assay is useful for monitoring of immunological aspects in the patient followup of more than one year after living donor liver transplantation (LDLT). Methods. Forty-nine patients, who underwent LDLT more than one year ago, were randomly screened by using IMK assay from January 2010 to December 2011, and the complete medical records of each patient were obtained. The CYP3A5 genotypes were examined in thirty-nine patients of them. Results. The mean ATP level of the IMK assay was significantly lower in the patients with infection including recurrence of hepatitis C (HCV) () than in those without infection (): 185 versus 350 ng/mL (), while it was significantly higher in the patients with rejection () than in those without rejection (): 663 versus 306 ng/mL (). The IMK assay showed favorable sensitivity/specificity for infection (0.909/0.842) as well as acute rejection (1.0/0.911). CYP3A5 genotypes in both recipient and donor did not affect incidence of infectious complications. Conclusions. In the late phase of LDLT patients, the IMK assay is very useful for monitoring immunological aspects including bacterial infection, recurrence of HCV, and rejection.http://dx.doi.org/10.1155/2013/982163
spellingShingle Shugo Mizuno
Yuichi Muraki
Kaname Nakatani
Akihiro Tanemura
Naohisa Kuriyama
Ichiro Ohsawa
Yoshinori Azumi
Masashi Kishiwada
Masanobu Usui
Hiroyuki Sakurai
Masami Tabata
Norihiko Yamamoto
Tomomi Yamada
Katsuya Shiraki
Yoshiyuki Takei
Tsutomu Nobori
Masahiro Okuda
Shuji Isaji
Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity
Clinical and Developmental Immunology
title Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity
title_full Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity
title_fullStr Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity
title_full_unstemmed Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity
title_short Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity
title_sort immunological aspects in late phase of living donor liver transplant patients usefulness of monitoring peripheral blood cd4 adenosine triphosphate activity
url http://dx.doi.org/10.1155/2013/982163
work_keys_str_mv AT shugomizuno immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT yuichimuraki immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT kanamenakatani immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT akihirotanemura immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT naohisakuriyama immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT ichiroohsawa immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT yoshinoriazumi immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT masashikishiwada immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT masanobuusui immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT hiroyukisakurai immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT masamitabata immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT norihikoyamamoto immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT tomomiyamada immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT katsuyashiraki immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT yoshiyukitakei immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT tsutomunobori immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT masahirookuda immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity
AT shujiisaji immunologicalaspectsinlatephaseoflivingdonorlivertransplantpatientsusefulnessofmonitoringperipheralbloodcd4adenosinetriphosphateactivity